Answers are grounded in this paper and cite their sources.
Depression is a common comorbidity in heart failure that worsens prognosis, but current evidence does not support withholding beta-blockers or guarantee that depression treatment improves cardiac outcomes.
Depression is prevalent in patients with heart failure, and the two conditions share underlying physiologic mechanisms. The prevalence of depression increases sharply with the severity of heart failure symptoms, an important consideration when confronting patients with worsening heart failure. Depression leads to poorer outcomes in patients with heart failure, including increased risk of poor functional status, hospital readmission, and death. Although beta-blockers are often implicated in the development and exacerbation of depression, evidence for this association is lacking, so withholding beta-blocker therapy is not recommended for patients with heart failure and depression. Evidence on whether therapy for depression also improves cardiac outcomes in heart failure patients is inconclusive, and further research on this question is needed. Nevertheless, early identification of depression in heart failure patients is imperative, as it can facilitate intervention attempts.
No takes yet. Share an insight, caveat, or question.
Marc A. Silver (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: